Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down

Bile Acids: Beyond Cholesterol Metabolism & Fat Absorption
Bookmark and Share

Pacific Biomarkers

Bile acids are well recognized as essential for regulating cholesterol homeostasis and the digestion and absorption of fat through the intestine. In recent years they have emerged as signaling molecules with endocrine functions, acting as ligands for the G-protein coupled receptor TGR5 and the nuclear receptor farnesoid X receptor (FXR). There is growing interest in bile acids as therapeutic targets for the treatment of obesity, type 2 diabetes, and hyperlipidemia.

In addition to their role in cholesterol metabolism and fat absorption, bile acids are important signaling molecules with endocrine functions. Bile acids regulate important pathophysiologic mechanisms leading to type 2 diabetes, obesity, and hyperlipidemia, hence making them attractive targets for novel therapeutics. Recognizing the importance of bile acids, PBI has developed a LC-MS/MS method to quantify multiple bile acids in serum and urine to support drug development in the above mentioned fields.

The original version of the White Paper can be found on the PBI website

Further Information

Related Content

Pacific Biomarkers CSO Elizabeth T. Leary Co-Authors Paper in March Issue of Clinical Chemistry
Article explores the contribution of assay methodologies in risk classification for cardiovascular disease.
Wednesday, March 09, 2011
Pacific Biomarkers' Dr. Amar A. Sethi Recognized by R&D Directions as One of Nine "Most Notable People in R&D"
Vice President of R&D singled out for work in seeking clues to heart-disease risk.
Thursday, March 03, 2011
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!